The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Amgen; Celgene
Travel, Accommodations, Expenses - Celgene; Roche
 
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Myriad Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Teva (Inst)
PANTHER: Prospective randomized phase III trial of tailored and dose-dense versus standard tri-weekly adjuvant chemotherapy for high-risk breast cancer in the modern era of endocrine and anti-HER2 therapy.
 
Jonas C. S. Bergh
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
 
Theodoros Foukakis
No Relationships to Disclose
 
Gunter von Minckwitz
No Relationships to Disclose
 
Nils-Olof Bengtsson
No Relationships to Disclose
 
Birgitta Wallberg
No Relationships to Disclose
 
Tommy Fornander
Stock and Other Ownership Interests - Pfizer
 
Brigitte Mlineritsch
No Relationships to Disclose
 
Sabine Schmatloch
No Relationships to Disclose
 
Christian F. Singer
No Relationships to Disclose
 
Guenther G. Steger
Honoraria - Amgen; AstraZeneca; Novartis; Pfizer; Roche; Teva
Consulting or Advisory Role - AstraZeneca; Celgene; Novartis; Roche
Research Funding - Amgen; Boehringer Ingelheim; Lilly; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Novartis; Roche; Teva
 
Eva Karlsson
No Relationships to Disclose
 
Lena Carlsson
No Relationships to Disclose
 
Sibylle Loibl
No Relationships to Disclose
 
Michael Untch
No Relationships to Disclose
 
Mats Hellstrom
No Relationships to Disclose
 
Hemming Johansson
No Relationships to Disclose
 
Per Malmstrom
No Relationships to Disclose
 
Michael Gnant
Employment - Sandoz (I)
Honoraria - Amgen; AstraZeneca; GlaxoSmithKline; NanoString Technologies; Novartis; Roche
Consulting or Advisory Role - Accelsiors; AstraZeneca; Novartis
Speakers' Bureau - Amgen; AstraZeneca; GlaxoSmithKline; NanoString Technologies; Novartis; Roche
Research Funding - GlaxoSmithKline; Novartis; Pfizer; Roche; Sanofi; Smiths Medical
 
Richard Greil
Consulting or Advisory Role - Amgen; AOP Orphan Pharmaceuticals; Baxalta; Boehringer Ingelheim; Celgene; Merck; MSD; Mundipharma; Novartis; Roche; Takeda
Speakers' Bureau - Amgen; Baxalta; Boehringer Ingelheim; Celgene; Merck; MSD; Novartis; Roche; Takeda
Research Funding - AB Science (Inst); Abbvie (Inst); Acerta Pharma (Inst); Amgen (Inst); AOP Orphan Pharmaceuticals (Inst); ARIAD (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); MorphoSys (Inst); MSD (Inst); Novartis (Inst); Onconova Therapeutics (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); XBiotech (Inst)
 
Volker Moebus
No Relationships to Disclose